BUZZ-US-listed Novo shares slip after company flags sharp 2026 sales drop

Reuters01:48
BUZZ-US-listed Novo shares slip after company flags sharp 2026 sales drop

** U.S.-listed shares of Danish drugmaker Novo Nordisk NOVOb.CO fall 13.8% to $50.83

** Novo expects 2026 sales to fall between 5% and 13%, as competition in obesity drugs intensifies; analysts on average expect sales to decline 2% for the year

** Q4 operating profit down 14% at 31.7 billion crowns, while analysts estimate 31.2 billion

** Shares of rival Eli Lilly LLY.N fall 3.4% in afternoon trading

** Obesity drug developers Structure Therapeutics GPCR.O and Altimmune ALT.O down 5.4% each, Viking Therapeutics VKTX.O down 3.7%, Amgen AMGN.O slip 1.4%

** Novo shares down ~42% in 2025

($1 = 6.3190 Danish crowns)

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment